Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China

BMC Health Services Research

Zhang Shu-qiang²  Zhu Jin-xiu³  Yu Mei-ling³  Liu Yan³  Ding Feng³  Jiang Xiao-dong³  Shi Qing-ping¹ 

[1] Education and Research Center, Bengbu Medical College, Bengbu 233000, China;Center of Adverse Drug Reaction monitoring, Bengbu Food & Drug Administration, Bengbu 233000, China;Department of Pharmacy, the first Affiliated Hospital of Bengbu Medical College, 287 Zhihuai Road, Bengbu 233004, China

关键词: Pharmacoeconomic;    Tertiary care teaching hospital;    Hospitalized patients;    Direct medical cost;    Adverse drug reaction;   

Others  :  1134106
DOI  :  10.1186/1472-6963-14-73

 received in 2013-08-14, accepted in 2014-02-14,  发布年份 2014

【 摘 要 】

Background

Adverse drug reactions (ADRs) are a leading cause of morbidity in developed countries and represent a substantial burden on health-care resources. Many countries spent 15% to 20% of their hospital budgets to treat drug complications. However, few studies have measured the pharmacoeconomic effects of ADRs on hospitalized patients in China. The study estimates the costs of ADRs as identified from the spontaneous voluntary reports completed from healthcare professionals. To do so, we calculate these costs, determine the sum of Medicare payments and their proportion of total healthcare spending, and evaluate the incidence of ADRs, characteristics of hospitalized ADR patients, and outcomes of ADRs in China.

Methods

This retrospective survey studied patients who experienced ADRs during their hospitalization at a Chinese tertiary-care teaching hospital. The patients were divided into group A and group B according to general ADRs and serious ADRs in Provisions for Adverse Drug Reaction Monitoring and Reporting. The direct costs included treatment fees, inspection fees, laboratory fees, materials fees, bed charges, drug charges, nursing care, meals, and other expenses and the sunk-cost losses were calculated according to the hospital information system (HIS). Indirect costs of ADR treatment were calculated according to the human capital approach. The epidemiological characteristics of ADRs were evaluated.

Results

2739 were diagnosed with ADR during the study period, which translates to an ADR rate of 0.81%. The total socioeconomic loss from 2739 cases of ADR was estimated at ¥817401.69, consisting of direct costs of ¥603252.81 and indirect costs of ¥214148.88. On average, the costs per patient amounted to ¥196.10 in group A, ¥7032.29 in group B. The sum of medicare payment and proportion were ¥219061.13 (65.23%) and ¥105422.02 (39.42%) in group A and B. The ADR incidence in old-age patients was significantly higher than in other age groups (P < 0.0001). The most common drug class associated with ADRs represented antibiotics (957 patients, 34.94%).

Conclusions

The costs of especially severe ADRs could not be ignored, and in this hospital 0.13% of patients were diagnosed with ADRs associated with relatively higher direct costs than who suffered from mild ADRs, largely due to extended hospitalization.

【 授权许可】

   
2014 Qing-ping et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Beijer HJ, de Blaey CJ: Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002, 24:46-54.
• [2]Dormann H, Mulh-Selbach U, Krebs S, et al.: Incidence and costs of adverse drug reactions during hospitalization: Computerized monitoring versus stimulated spontaneous reporting. Drug Saf 2000, 22:161-168.
• [3]Bordet R, Gautier S, le Louet H, et al.: Analysis of the direct cost of adverse drug reactions in hospitalized patients. Eurff Clin Pharmacol 2001, 56:935-941.
• [4]White TJ, Arakelian A, Rho J: Counting the costs of drug-related adverse events. Pharmacoeconomics 1999, 15:445-448.
• [5]Johnson JA, Bootman JL: Drug-related morbidity and mortality. A cost-of-illness model. Arch Inter Med 1995, 155:1949-1956.
• [6]Erns FR, Grizzle AJ: Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc 2001, 41(2):192-199.
• [7]Griffin JP: Survey of the spontaneous adverse drug reaction reporting schemes in fifteen countries. Br J Clin Pharmacol 1986, 22(S1):S83-S100.
• [8]Hartwig SC, Siegel J, Schneider PJ: Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992, 49:2229-2232.
• [9]Hoonhout LHF, de Bruijne MC, Wagner C, et al.: Direct medical costs of adverse events in Dutch hospitals. BMC Health Serv Res 2009, 9(27):1-10. doi:10.1186/1472-6963-9-27
• [10]Wen-jun H, Ji-fen C: Current situation analysis on adverse drug reaction reporting and monitoring in our country. J Chin Pharmacovigil 2012, 9:92-94.
• [11]Lei H, Li-chen G, Wei Z, et al.: Advances in pharmacogenomics of cytochrome P450 oxidoreductas. Chin J Clin Pharmacol Ther 2012, 17(7):820-827.
• [12]Jing Z, Peng-yuan W, Yi-sheng P, et al.: The adverse drug reaction monitoring in hospitals. Chin J Pharmacovigil 2013, 10(1):54-56.
• [13]Ministry of health of the people’s Republic of China: People’s Republic of China ministry of health. Provisions for adverse drug reaction monitoring and reporting. 2010. http://www.sda.gov.cn/WS01/CL0053/62621.html webcite
• [14]Naranjo CA, Busto U, Sellers EM, et al.: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30:239-245.
• [15]WHO Collaborating Centre for Drug Statistics Methodology: Completed ATC Index. 2005. http://www.whocc.no/atcddd/ webcite
• [16]National Adverse Drug Reaction Monitoring Center: WHO Adverse Reaction Terminology. Peking: China Medicine and Technology Press; 2003.
• [17]Jang D, Mattila AS, Bai B: Restaurant membership fee and customer choice: the effects of sunk cost and feelings of regret. Int J Hosp Manag 2007, 26(3):687-697.
• [18]McElhinney D, Proctor T: Concept of entrapment and decision-making. Manag Decis 2005, 43(2):189-202.
• [19]Li K, Zhang HH, Lian WG: Several important cost concepts in hospitals’ cost decision-making with examples analyzed. Mod Hosp 2004, 4(4):66-68.
• [20]Jie LIU, Hai GU: Study on cost calculation of medicine ill-effects. Health Econ Res 2007, 2:18-19.
• [21]Pirmohamed M, James S, Meakin S, et al.: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. Br Med J 2004, 329:15-19.
• [22]Oshikoya KA: Adverse drug reaction in children: types, incidence and risk factors. Nig J Paediatr 2006, 33:29-35.
• [23]Martinez-Mir I, Garcia-Lopez M, Palop V, Ferrer JM, Rubio E, Morales-Olivas FJ: A prospective study of adverse drug reactions in hospitalized children. Br J Clin Pharmacol 1999, 47:681-688.
• [24]Rawlins MD: Spontaneous reporting of adverse drug reactions. I: the data. Br J Clin Pharmacol 1988, 26:7-11.
• [25]Jose J, Rao PGM: Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. Pharmacol Res 2006, 54:226-233.
• [26]van Grootheest K, Olsson S, Couper M, de Jong-van den Berg L: Pharmacists’ role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf 2004, 13:457-464.
• [27]Chan ALF, Lee HY, et al.: Cost evaluation of adverse drug reactions in hospitalized patients in Taiwan: a prospective, descriptive, observational study. Curr Ther Res 2008, 69:118-129.
• [28]Zhang K, Xu Y, Wu B, et al.: Analysis of 1001 cases of adverse drug reactions/events induced by traditional Chinese Medicine Injections. Chin Pharm 2013, 22(5):70-72.
• [29]Jiang DU, Kuang SH: Analysis of 773 case reports of adverse drug reactions/events in our hospital. Chin Licensed Pharm 2013, 10(10):11-18.
• [30]Wang L, Yin T, Zhu MW: Retrospective study of adverse drug reactions of Shenmai injection. Cent South Pharm 2007, 5:275-279.
• [31]Lee HY, Tay LK, Thirumoorthy T, Pang SM: Cutaneous adverse drug reactions in hospitalised patients. Singapore Med J 2010, 51(10):767-774.
• [32]Ze CC: Analysis of 140 cases of adverse drug reaction reports and cost. J Chin Pharmacovigil 2010, 7(9):561-563.
• [33]Changda L, Shusen Z, Jianghong X: Analysis on ADR reports in Ganzhou city during 2011. Chin Pharm Aff 2012, 26(12):1421-1425.
• [34]Zhou JJ, Zhang R, Ji Y, et al.: Utilization of antibacterials in central hospital of Shanghai Xuhui district during 2008–2010. Pharm Care Res 2012, 12(1):21-24.
• [35]Patel H, Bell D, Molokhia M, et al.: Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998–2005. BMC Clin Pharmacol 2007, 79:1-11.
• [36]Yi G: Renminbi exchange rates and relevant institutional factors. Cato J 2008, 28(2):187-196.
• [37]Lagnaoui R, Moore N, Fach J, et al.: Adverse drug reactions in a department of systemic diseases oriented internal medicine: prevalence, incidence, direct costs and availability. Eur J Clin Pharmacol 2000, 56(2):181-186.